Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ravulizumab study in adults with trigger-associated thrombotic microangiopathy
NL-OMON51930Phase 3Withdrawn
- Sponsor
- PPD
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thrombotic microangiopathies (TMA) comparing Ravulizumab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Complete TMA Response during the 26-week randomized Treatment Period. Planned start Mar 2021; status: withdrawn.
02
Drugs
ravulizumab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on NL-OMON51930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51930.